Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-06-21
2011-06-21
Wang, Chang-Yu (Department: 1649)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S001200, C514S001300, C514S013300, C514S020800, C424S009340, C530S300000
Reexamination Certificate
active
07964557
ABSTRACT:
The present invention provides new methods of treating wet type of age related macular degeneration by administering adiponectin (APN) or a functional fragment derived therefrom. One of the pathological complications of age related macular degeneration (AMD) is choroidal angiogenesis or choroidal neovascularization (CNV). The inventors discovered that the level of APN expression is significantly lower in the choroids of the laser-induced mouse model of choroidal angiogenesis or choroidal neovascularization (CNV) than that of the control mice and that administration of recombinant adiponectin (rAPN) or a peptide derived from the globular domain of the intact APN protein to the mouse model of CNV reduced the size of CNV significantly. These studies are the first to demonstrate the inhibitory effect of adiponectin on choroidal angiogenesis and thus provide the basis for treating a condition or disease involving angiogenesis, particularly age related macular degeneration, with administration of adiponectin.
REFERENCES:
patent: 4683195 (1987-07-01), Mullis et al.
patent: 4683202 (1987-07-01), Mullis et al.
patent: 4800159 (1989-01-01), Mullis et al.
patent: 5869330 (1999-02-01), Scherer et al.
patent: 6344441 (2002-02-01), Bihain et al.
patent: 6448221 (2002-09-01), Sheppard et al.
patent: WO 03/055916 (2003-07-01), None
patent: WO 04/056861 (2004-07-01), None
Burgess et al. J of Cell Bio. 1990, 111:2129-2138.
Bowie et al. Science, 1990, 247:1306-1310.
Pawson et al. 2003, Science 300:445-452.
Accession NCBI No. AAK58902 (2001).
Accession NCBI No. AAK92202 (2001).
Accession NCBI No. AAL09702 (2001).
Accession NCBI No. BAB22597 (2006).
Accession NCBI No. NP—004788 (2008).
Ausubel et al. (Eds.) (2008)Current Protocols in Molecular Biology, Greene Publishing and Wiley Interscience, New York—(Table of Contents only).
Berg et al. (2002)Trends Endocrinol. Metab. 13, 84-89.
Bora et al. (2005)J. Immunol. 174:491-497.
Brakenhielm et al. (2004)Proc. Natl Acad. Sci. USA. 101: 2476-2481.
Campochiaro et al. (2000) 184:301-310.
Cao et al. (2001)PNAS98:6390-6395.
D'Amore et al. (1994)Invest. Opthalmol. Vis. Sci. 35:3874-3879.
Espinosa-Heidmann et al. (2003)Invest. Opthamol. Vis. Sci.44:3586-3592.
Fine et al.(2000)N. Engl. J. Med. 342:483-492.
Fischer (1983)Meth. Enzymol. 100:424-430.
Fruebis et al. (2001)PNAS98:2005-2050.
Goodman and MacDonald (1979)Meth. Enzymol. 68:75-90.
Jackson et al. (1997)FASEB J. 1997 11:457-465.
Jain RK (2005)Science307:58-62.
Liu et al. (2004)Curr. Opin. Ophthalmol15:221-226.
Maeda et al. (2001)Nat. Med. 8:731-737.
Maeda et al. (1996)BBRC221:286-28.
Matsubara et al. (2002)J Clin Endocrinol Metab. 87, 2764-2769.
Mousa et al. (2004)Current Pharmaceutical Design10:1-9.
Nakano et al. (1996)J. Biochem. 120: 803-812.
Ouchi et al. (2004)J. Biol. Chem. 279:1304-9.
Pierce et al. (1995)PNAS92:905-909.
Rose et al. (1996)Clinical CancerResearch2:1751-1756.
Rose et al. (2004)Obes. Rev.5:153-65.
Sakurai et al. (2003)Invest. Opthamol. Vis. Sci.44:3578-3585.
Sandri-Goldin et al. (1983)Meth. Enzymol. 101:402-411.
Scherer et al. (1995)J. Biol. Chem. 270:26746-26749.
Shibata et al. (2004)J. Biol. Chem. 279:28670-4.
Wei et al. (1983)J. Biol. Chem. 258:13006-13512).
Weyer et al. (2001)J Clin Endocrinol Metab. 86:1930-1935.
Xu et al. (2003)J. Clin. Invest. 112(1): 91-100.
Yamauchi et al. (2001)Nat. Med. 7:941-946.
Yi et al. (1997)Graefe's Arch. Clin. Exp. Opthamol. 235:313-319.
Yilmaz et al. (2004)Eur. J. Endocrinol. 151:135-140.
Yilmaz et al. (2004)Eur. J. Endocrinol. 152:233-240.
Yokota et al. (2000)Blood96:1723.
Ferris et al. (1984)Arch. Opthalmol. 102:1640-1642.
Larionov, O.A. et al. (1982)Genetika18(3):349-59—(English Abstract).
Maniatis et al. (1980)Meth. Enzymol. 65:299-305.
Metzger et al. (1988)Nature, 334: 31-36.
Saiki et al. (1985)Science230:1350-1354.
Shortle, D. et al. (1981)Annu. Rev. Genet. 15:265-94.
Stupack et al. (2004)Curr Top Dev Biol. 64:207-238.
Bora Nalini S.
Bora Puran S.
Kaplan Henry J.
Greenlee Sullivan PC
University of Louisville Research Foundation Inc.
Wang Chang-Yu
LandOfFree
Inhibition of wet type age related macular degeneration... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibition of wet type age related macular degeneration..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibition of wet type age related macular degeneration... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2667766